CN1020752C - 后天性免疫缺乏综合征(爱滋病)疫苗 - Google Patents

后天性免疫缺乏综合征(爱滋病)疫苗 Download PDF

Info

Publication number
CN1020752C
CN1020752C CN86106632A CN86106632A CN1020752C CN 1020752 C CN1020752 C CN 1020752C CN 86106632 A CN86106632 A CN 86106632A CN 86106632 A CN86106632 A CN 86106632A CN 1020752 C CN1020752 C CN 1020752C
Authority
CN
China
Prior art keywords
lav
htlv iii
virus
cell
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN86106632A
Other languages
English (en)
Chinese (zh)
Other versions
CN86106632A (zh
Inventor
胡水洛克
安东尼F·波居欧
林达·梅迪逊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncogen LP
Original Assignee
Oncogen LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen LP filed Critical Oncogen LP
Publication of CN86106632A publication Critical patent/CN86106632A/zh
Application granted granted Critical
Publication of CN1020752C publication Critical patent/CN1020752C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN86106632A 1985-09-25 1986-09-25 后天性免疫缺乏综合征(爱滋病)疫苗 Expired - Fee Related CN1020752C (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US77990985A 1985-09-25 1985-09-25
US779909 1985-09-25
US84298486A 1986-03-27 1986-03-27
US842984 1986-03-27
US90521786A 1986-09-09 1986-09-09
US905217 1986-09-09

Publications (2)

Publication Number Publication Date
CN86106632A CN86106632A (zh) 1987-05-13
CN1020752C true CN1020752C (zh) 1993-05-19

Family

ID=27419757

Family Applications (1)

Application Number Title Priority Date Filing Date
CN86106632A Expired - Fee Related CN1020752C (zh) 1985-09-25 1986-09-25 后天性免疫缺乏综合征(爱滋病)疫苗

Country Status (22)

Country Link
CN (1) CN1020752C (fi)
AT (1) ATA256786A (fi)
CH (1) CH676247A5 (fi)
DE (1) DE3690508T1 (fi)
DK (1) DK455486A (fi)
ES (2) ES2002490A6 (fi)
FI (1) FI863848A (fi)
FR (1) FR2587720A2 (fi)
GB (1) GB2181435B (fi)
GR (1) GR862412B (fi)
HU (1) HU205780B (fi)
IE (1) IE59314B1 (fi)
IL (1) IL80073A (fi)
IT (1) IT1195829B (fi)
MY (1) MY103182A (fi)
NL (1) NL8602422A (fi)
NO (1) NO863803L (fi)
NZ (1) NZ217645A (fi)
PT (1) PT83434B (fi)
SE (4) SE8604007L (fi)
WO (1) WO1987002038A1 (fi)
YU (1) YU46753B (fi)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1105015C (zh) * 1995-09-06 2003-04-09 库夫施泰因模板技术股份公司 网板印刷模板的制备方法

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3650011T2 (de) * 1985-04-08 1994-11-17 Genetic Systems Corp EXPRESSION UND DIAGNOSE MIT gag-KODIERTEN PEPTIDEN, DIE MIT ANTIKÖRPERN GEGEN LAV IMMUNOLOGISCH REAKTIV SIND.
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
US4925784A (en) * 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
US4983387A (en) * 1986-05-19 1991-01-08 Viral Technologies Inc. HIV related peptides, immunogenic antigens, and use therefor as subunit vaccine for AIDS virus
ATE107861T1 (de) * 1986-09-19 1994-07-15 Oncogen Verwendung von aktivierten t-lymphozyten zur vorbereitung einer pharmazeutischen zusammensetzung zur behandlung von aids.
IE872748L (en) * 1986-10-16 1988-04-16 Arjomari Europ Polypeptides derived from the evvelope gene of human¹immunodeficiency virus in recombinant baculovirus infected¹insect cells
JPS63258575A (ja) * 1986-12-15 1988-10-26 レプリゲン　コーポレーション 昆虫細胞中でつくられる組換えｈｉｖエンベロープタンパク
WO1988005440A1 (fr) * 1987-01-16 1988-07-28 Institut Pasteur Peptides ayant des proprietes immunologiques 2-hiv-2
FR2610632B1 (fr) * 1987-02-11 1990-12-21 Pasteur Institut Peptides caracteristiques des retrovirus d'immunodeficience humaine (virus hiv) leurs applications au diagnostic des infections dues a certains de ces virus et, le cas echeant, a la vaccination contre le sida
US5681713A (en) * 1987-05-08 1997-10-28 Smithkline Beecham Corporation Expression of heterologous proteins in Drosophila cells
GB8714802D0 (en) * 1987-06-24 1987-07-29 Proteus Biotech Ltd Synthetic polypeptides
DE10399031I1 (de) * 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
FR2620030B1 (fr) * 1987-09-07 1990-03-23 Transgene Sa Vecteur d'expression des proteines du virus hiv-2, un agent causal du sida, culture cellulaire infectee ou transformee par ce vecteur, proteines obtenues, vaccin et anticorps obtenus
IL89118A0 (en) * 1988-02-03 1989-08-15 Microgenesys Inc Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
US5763160A (en) * 1988-02-12 1998-06-09 United Biomedical, Inc. Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines
ATE110112T1 (de) * 1988-05-06 1994-09-15 Ferropas Ag Verfahren und systeme zur herstellung von hiv- antigenen.
US5043262A (en) * 1988-05-12 1991-08-27 Dana Farber Cancer Institute Protein, sequences containing the VPU gene therefore, vectors, methods of preparation and use
AP129A (en) * 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US5631154A (en) * 1988-06-10 1997-05-20 Therion Biologics, Incorporated Self assembled, defective, non-self-propagating lentivirus particles
WO1989012095A1 (en) * 1988-06-10 1989-12-14 Applied Biotechnology, Inc. A method of evaluating recombinant vaccines against immunodeficiency virus
US5747324A (en) * 1988-06-10 1998-05-05 Therion Biologics Corporation Self-assembled, defective, non-self-propagating lentivirus particles
US5614404A (en) * 1988-06-10 1997-03-25 Theriod Biologics, Incorporated Self-assembled, defective, non-self-propagating lentivirus particles
US5665577A (en) * 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
WO1990012880A1 (en) * 1989-04-18 1990-11-01 Applied Biotechnology, Inc. Generation of hybrid genes and proteins by virus-mediated recombination
WO1990015141A2 (en) * 1989-06-01 1990-12-13 Applied Biotechnology, Inc. Self-assembled, defective, non-self-propagating viral particles
GB8923123D0 (en) * 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
US5981276A (en) * 1990-06-20 1999-11-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US5840312A (en) * 1991-05-02 1998-11-24 Institut Pasteur Recombinant Bacillus anthracis strains unable to produce the lethal factor protein or edema factor protein
FR2676068B1 (fr) * 1991-05-02 1994-11-04 Pasteur Institut Souches recombinantes immunogenes de b. anthracis - compositions immunogenes les contenant.
EP0611397B1 (en) * 1991-11-08 2002-06-19 PHARMACIA & UPJOHN COMPANY Feline leukemia virus vaccines
DE4405810A1 (de) 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
AU5259796A (en) 1995-02-10 1996-08-27 Worcester Foundation For Biomedical Research, Inc. Delivery of exogenous compounds
US6013506A (en) * 1995-06-05 2000-01-11 Wardley; Richard C. Feline leukemia virus vaccines
US5741492A (en) * 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US6723558B1 (en) 1996-01-23 2004-04-20 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
MXPA04005865A (es) 2001-12-19 2004-09-13 Nektar Therapeutics Suministro de aminoglucosidos a los pulmones.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3485810T2 (de) * 1983-05-27 1992-12-10 Texas A & M University Syst Verfahren zur herstellung eines rekombinanten baculovirus-expressionsvektors.
US4662514A (en) * 1983-11-01 1987-05-05 Charleswater Products, Inc. Electrically conductive polymeric tubes for static sensitive electronic devices
US9328391B1 (en) * 1984-08-22 2016-05-03 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Cloning and expression of HIV-1 DNA
IL76082A (en) * 1984-08-22 1991-07-18 Us Health Molecular clones of the genome of htlv-iii and a process for the preparation thereof
DE3588254T2 (de) * 1984-10-18 2008-06-26 Institut Pasteur GAG-Antigen und dessen Verwendung zum Nachweis von LAV-Infektion, sowie in immunogenen Zusammensetzungen
GB8501473D0 (en) * 1985-01-21 1985-02-20 Pasteur Institut Cloned dna sequences
CA1341423C (en) * 1984-10-31 2003-03-04 Paul A. Luciw Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
EP0187041B1 (en) * 1984-12-24 1996-05-15 Genentech, Inc. Fusions of AIDS-related polypeptides
US4774175A (en) * 1985-03-01 1988-09-27 Centocor, Inc. Immunochemical methods for the detection of antibody against HTLV-III
DK171119B1 (da) * 1985-04-19 1996-06-17 Hoffmann La Roche AIDS-viruskappeprotein, ekspressionsvektor bærende viruskappeproteinet, transformanter transformeret med ekspressionsvektoren, fremgangsmåde til fremstilling af viruskappeproteinet, fremgangsmåde til detektion af AIDS-antistoffer, fremgangsmåde til bestemmelse af AIDS-virus, vaccine mod AIDS, antistoffer mod viruskappeproteinet samt anvendelse af dette til fremstilling af en vaccine og til testnin
FR2586427B1 (fr) * 1985-08-20 1988-12-09 Pasteur Institut Sequences de nucleotides et de polypeptides issus du virus visna et leur application a des essais de diagnostic et a la production de compositions immunogenes

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1105015C (zh) * 1995-09-06 2003-04-09 库夫施泰因模板技术股份公司 网板印刷模板的制备方法

Also Published As

Publication number Publication date
CH676247A5 (fi) 1990-12-28
GB2181435B (en) 1990-01-10
GB2181435A (en) 1987-04-23
IL80073A (en) 1995-01-24
GR862412B (en) 1987-01-23
NO863803D0 (no) 1986-09-24
SE8604007D0 (sv) 1986-09-23
IE862525L (en) 1987-03-25
DK455486D0 (da) 1986-09-24
NZ217645A (en) 1991-11-26
ES2006941A6 (es) 1989-05-16
FR2587720B2 (fi) 1995-02-10
SE9102974L (sv) 1993-04-15
SE9102976L (sv) 1993-04-15
YU46753B (sh) 1994-05-10
DE3690508T1 (fi) 1988-06-23
YU165486A (en) 1989-08-31
SE8604007L (sv) 1987-03-26
GB8622987D0 (en) 1986-10-29
ES2002490A6 (es) 1988-08-16
PT83434A (en) 1986-10-01
IL80073A0 (en) 1986-12-31
HUT42133A (en) 1987-06-29
SE9102974D0 (sv) 1991-10-14
FR2587720A2 (fr) 1987-03-27
CN86106632A (zh) 1987-05-13
SE9102975D0 (sv) 1991-10-14
NL8602422A (nl) 1987-04-16
IT8667730A0 (it) 1986-09-24
NO863803L (no) 1987-03-26
SE9102976D0 (sv) 1991-10-14
IE59314B1 (en) 1994-02-09
MY103182A (en) 1993-05-29
PT83434B (pt) 1988-07-29
HU205780B (en) 1992-06-29
WO1987002038A1 (en) 1987-04-09
ATA256786A (de) 1995-05-15
IT1195829B (it) 1988-10-27
FI863848A (fi) 1987-03-26
DK455486A (da) 1987-03-26
FI863848A0 (fi) 1986-09-24
SE9102975L (sv) 1993-04-15

Similar Documents

Publication Publication Date Title
CN1020752C (zh) 后天性免疫缺乏综合征(爱滋病)疫苗
CN1056878C (zh) 重组火鸡疱疹病毒及其衍生的活载体疫苗
CN1229501C (zh) Hiv多包膜蛋白疫苗的重组痘苗载体混合物
US4870023A (en) Recombinant baculovirus occlusion bodies in vaccines and biological insecticides
CN1040126C (zh) 一种蛋白的制备方法
CN1018845B (zh) 病毒疫苗
EP0349594A1 (en) Recombinant baculovirus occlusion bodies in vaccines and biological insecticides
CN1333873A (zh) Hiv－特异的t－细胞诱导
JPH06500232A (ja) 自己集合性複製欠陥型ハイブリッドウイルス粒子
CN1041326C (zh) 制备cav核酸序列或氨基酸序列的方法
CN1055501C (zh) 重组禽痘病毒,培养被上述病毒感染的细胞以及从上述病毒得到的家禽疫苗
CN1216064A (zh) 合成的hiv基因
KR20230034933A (ko) Covid-19에 대한 보호를 위한 약독화된 폭스바이러스 벡터 기반 백신
JP2000506727A (ja) 組換え生ネコ免疫不全ウイルスおよびプロウイルスｄｎａワクチン
CA2033175C (en) Self-assembled, defective, non-self-propagating viral particles
CN1295339C (zh) 减毒痘苗病毒天坛株载体及制备方法和应用
CN1292071C (zh) 减毒痘苗病毒天坛株载体及制备方法和应用
US6331616B1 (en) Nucleic acids obtained from the envelope coding region of feline immunodeficiency virus molecular clone designated JSY3
Vlastos et al. VP1 pseudocapsids, but not a glutathione‐S‐transferase VP1 fusion protein, prevent polyomavirus infection in a T‐cell immune deficient experimental mouse model
CN1054613A (zh) 一种在预防和治疗人体逆转录病毒中作为抗病毒剂和免疫原的非复制性的重组逆转录病毒颗粒
CN1636013A (zh) 可编码hiv辅助蛋白的dna疫苗
CN1527883A (zh) 基于野兔痘的载体疫苗
CN1668736A (zh) 不含异源成分的gM－阴性EHV突变体
CN110468111B (zh) 一种展示CyHV-2膜蛋白的重组杆状病毒及其制备方法和应用
CN1918288A (zh) 表达sars免疫原的载体、含所述载体或其表达产物的组合物、制备和使用方法和实验

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee